For adults with recent NCIS or high-risk TIA in combination with antiplatelet therapy
Frequently asked questions
Find answers to the most commonly asked questions about SUNHARBO®.
PLACEHOLDER
Mechanism of action
SUNHARBO is the first approved medicine to target factor XIa, representing a new approach to reducing the risk of ischemic stroke. SUNHARBO is an inhibitor of activated factor XIa (FXIa). FXIa inhibition reduces amplification of thrombin generation. In preclinical models, factor XIa inhibition targets more pathological clotting (thrombosis) with lesser impact on normal clotting response (hemostasis).1
Treatment initiation
SUNHARBO is for adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA).1
Administration
SUNHARBO should be interrupted at least 24 hours before elective surgery or invasive procedure. SUNHARBO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.1
There is no reversal agent for SUNHARBO.4
Efficacy
Risk of recurrence remains high. ~1 in 5 survivors will have another stroke within 5 years. SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent NCIS or high-risk TIA.1,5,6
Safety
The rate of GI bleeding was higher in the SUNHARBO + APT group compared to the placebo APT group (2.7 vs 2.1 per 100 patient-years) with a hazard ratio of 1.3 (95% CI: 1.0–1.6). The majority of gastrointestinal bleeding in the SUNHARBO + APT group (74%) were clinically relevant non-major or minor bleeding, and the most frequent bleeding site was of rectal origin.1
Considerations
For digoxin and sensitive P-gp substrates where minimal concentration changes may increase the risk of adverse reactions, follow the recommendation in their approved product labeling.
Avoid concomitant use with combined P-gp and strong CYP3A4 inducers, which decreases exposure to SUNHARBO and may lead to loss of efficacy.
There are no available data on SUNHARBO use in pregnant women. There are risks to the mother associated with untreated non-cardioembolic ischemic stroke or TIA and risk of bleeding in the mother and fetus or neonate associated with use of anticoagulants during pregnancy.
Advise patients who are exposed to SUNHARBO during pregnancy to contact Bayer Healthcare Pharmaceuticals Inc. at 1-888-842-2937.
Because of the potential for serious adverse reactions in nursing infants, including bleeding, advise patient not to breastfeed during treatment with SUNHARBO and for 5 days after the last dose.
Storage and handling
SUNHARBO 50 mg tablets are supplied as dark-orange, film-coated, oval, biconvex tablets marked "BAY" on one side and "50" on the other side. SUNHARBO tablets are available in the following package sizes:
- 30-count bottle
- 100-count hospital pack (10 blister cards containing 10 tablets each)
Store SUNHARBO at room temperature (68°F to 77°F). It may spend brief periods outside of that range (59°F to 86°F).
Store in original bottle. Do not remove desiccant.
Access
The coverage process can begin before discharge. For any questions, reach out to your SUNHARBO representative.
SUNHARBO will be available starting from mid to late November. If a pharmacy does not have it in stock, they can order it from their primary wholesaler for delivery within 24 to 48 hours. Go through the normal ordering process on 11/24/26.
Glossary of terms
APT
Antiplatelet therapy
- Current standard of care
Clinically relevant non-major bleeding
- Clinically overt bleeding meeting at least one of the following criteria: requiring treatment by a healthcare professional, leading to hospitalization or increased level of care, requiring change in antithrombotic therapy, and is not major bleeding
ISTH Major Bleeding
As defined by the International Society on Thrombosis and Haemostasis (ISTH) classification, which includes:
- Fatal bleeding and/or
- Symptomatic bleeding in a critical area or organ and/or
- Clinically overt bleeding resulting in a decrease in hemoglobin level of at least 2 g/dL or that led to the transfusion of at least 2 units of packed red cells or whole blood
Minor bleeding
- All other overt bleedings not meeting the above criteria for major or clinically relevant non-major bleeding
mRS
Modified Rankin Scale
- The most widely used outcome scale in acute stroke trials, the mRS is a 7-level, clinician-reported, measure of global disability
NCIS
Non-cardioembolic ischemic stroke
- The majority of new strokes in the United States are non-cardioembolic
NIHSS
National Institutes of Health Stroke Scale
- Used to determine stroke severity. A numeric scale from 0 (alert) to 3 (unresponsive) records the person’s performance in 11 categories, such as sensory and motor ability
TIA
Transient ischemic attack
- Patients who have a TIA have a greater risk of stroke
100 patient-years
Patient-years combine the number of patients in a study and the amount of time they are followed.
- For example, 100 patients followed for 1 year each or 50 patients followed for 2 years each both equal 100 patient-years. Reporting events per 100 patient-years helps account for differences in follow-up time and allows for a more standardized comparison between treatment groups. A rate of 1.1 events per 100 patient-years means approximately 1.1 events occurred during a combination of patient and years that represent 100.
References
- SUNHARBO (asundexian) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2026.
- Arsava EM, Kim GM, Oliveira-Filho J, et al. Prediction of early recurrence after acute ischemic stroke. JAMA Neurol. 2016;73(4):396-401. doi:10.1001/jamaneurol.2015.4949
- Edwards JD, Kapral MK, Fang J, Swartz RH. Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack. CMAJ. 2017;189(29):E954-E961. doi:10.1503/cmaj.161142
- Levy JH, Shaw JR, Castellucci LA, et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2024;22(10):2889-2899. doi:10.1016/j.jtha.2024.07.009
- Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Barone Gibbs B, Beaton AZ, Boehme AK, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347-e913. doi:10.1161/CIR.0000000000001209
- Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(8):105935. doi:10.1016/j.jstrokecerebrovasdis.2021.105935